Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction
Open accessAbstract
BACKGROUND: Thyroid dysfunction is occasionally reported after the administration of nivolumab. We report on the incidence of and risk factors for nivolumab-induced thyroid dysfunction in patients with non-small lung cancer. PATIENTS AND METHODS: A total of 82 patients who received nivolumab between January 2016 and December 2016 at the Kanagawa Cancer Center were included. Prior to nivolumab treatment, 72 patients had normal thyroid function. RESULTS: Among the 72 patients with normal thyroid function prior to nivolumab treatment, the incidence of thyroid dysfunction was 19.5%. There were no significant differences between patients in whom thyroid dysfunction had occurred regarding sex, age, nivolumab dose, or thyroid function prior to nivolumab administration. However, the total number of doses of nivolumab was significantly greater in patients who developed thyroid dysfunction after nivolumab treatment (p=0.03). CONCLUSION: The total number of doses administered may be a risk factor for the development of thyroid dysfunction after nivolumab therapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the literature, female gender is described as a risk factor for ICPi-induced thyroid dysfunction, although this is less pronounced than in spontaneous forms and is not described in all studies.
“In the literature, female gender is described as being a risk factor for ICPi-induced TD, although this is less pronounced than in spontaneous forms [7,46,47] and it is not described in all studies [11,48].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [48]
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222 · see citing works
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02272 · Cited by 226 · see citing works
Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., & Larkin, J. (2017) · Clinical Endocrinology · doi:10.1111/cen.13297 · Cited by 190 · see citing works
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
Yamauchi, I., Sakane, Y., Fukuda, Y., Fujii, T., Taura, D., Hirata, M., Hirota, K., Ueda, Y., Kanai, Y., Yamashita, Y., et al. (2017) · Thyroid · doi:10.1089/thy.2016.0562 · Cited by 169 · see citing works
Costa, R., Carneiro, B. A., Agulnik, M., Rademaker, A. W., Pai, S. G., Villaflor, V. M., Cristofanilli, M., Sosman, J. A., & Giles, F. J. (2017) · Oncotarget · doi:10.18632/oncotarget.13315 · Cited by 123 · see citing works
Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma
Okano, Y., Satoh, T., Horiguchi, K., Toyoda, M., Osaki, A., Matsumoto, S., Tomaru, T., Nakajima, Y., Ishii, S., Ozawa, A., et al. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0161 · Cited by 114 · see citing works
Nivolumab: A Review of Its Use in Patients with Malignant Melanoma
Deeks, E. D. (2014) · Drugs · doi:10.1007/s40265-014-0234-4 · Cited by 83 · see citing works
Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab
Narita, T., Oiso, N., Taketomo, Y., Okahashi, K., Yamauchi, K., Sato, M., Uchida, S., Matsuda, H., & Kawada, A. (2015) · The Journal of Dermatology · doi:10.1111/1346-8138.13028 · Cited by 51 · see citing works
Nivolumab-induced thyroid dysfunction
Tanaka, R., Fujisawa, Y., Maruyama, H., Nakamura, Y., Yoshino, K., Ohtsuka, M., & Fujimoto, M. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw036 · Cited by 47 · see citing works
Costa, R. L. B., Carneiro, B. A., RADEMAKER, A. W., Agulnik, M., Villaflor, V. M., Matsangou, M., Pai, S. G., Kalyan, A., Chae, Y. K., Chandra, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3064 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L., Barroso‐Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 546 · see citing works
How we treat endocrine complications of immune checkpoint inhibitors
Paschou, S. Α., Stefanaki, K., Ψαλτοπούλου, Θ., Liontos, M., Koutsoukos, K., Zagouri, F., Lambrinoudaki, I. V., & Dimopoulos, M. A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100011 · Cited by 74 · see citing works
Ma, C., Hodi, F. S., Giobbie‐Hurder, A., Wang, X., Zhou, J., Zhang, A., Zhou, Y., Mao, F., Angell, T. E., Andrews, C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0613 · Cited by 66 · see citing works
Lechner, M. G., Patel, A. Y., Hugo, W., Angell, T. E., Cheng, M. I., Pioso, M. S., Hoang, A. T., Yakobian, N., McCarthy, E. C., Chen, H.-C., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200244 · Cited by 56 · see citing works
Campredon, P., Mouly, C., Lusque, A., Bigay-Game, L., Bousquet, E., Mazières, J., & Caron, P. J. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2018.10.019 · Cited by 41 · see citing works
Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
Peiffert, M., Cugnet-Anceau, C., Dalle, S., Chikh, K., Assaad, S., Disse, E., Raverot, G., Borson-Chazot, F., & Abeillon-du Payrat, J. (2021) · Cancers · doi:10.3390/cancers13081944 · Cited by 33 · see citing works
“In the literature, female gender is described as being a risk factor for ICPi-induced TD, although this is less pronounced than in spontaneous forms [7,46,47] and it is not described in all studies [11,48].”
BackgroundThe changing clinical spectrum of endocrine adverse events in cancer immunotherapy
Chiloiro, S., Bianchi, A., Giampietro, A., Milardi, D., Marinis, L. D., & Pontecorvi, A. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.10.009 · Cited by 32 · see citing works
Garon-Czmil, J., Petitpain, N., Rouby, F., Sassier, M., Babai, S., Yelehe‐Okouma, M., Weryha, G., Klein, M., & Gillet, P. (2018) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12423 · Cited by 23 · see citing works
Kobayashi, K., Iikura, Y., Hiraide, M., Yokokawa, T., Aoyama, T., Shikibu, S., Hashimoto, K., Suzuki, K., Sato, H., Sugiyama, E., et al. (2020) · In Vivo · doi:10.21873/invivo.12083 · Cited by 20 · see citing works
Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
Dudzińska, M., Szczyrek, M., Wojas‐Krawczyk, K., Świrska, J., Chmielewska, I., & Zwolak, A. (2020) · Cancers · doi:10.3390/cancers12082314 · Cited by 18 · see citing works
Chmielewska, I., Dudzińska, M., Szczyrek, M., Świrska, J., Wojas‐Krawczyk, K., & Zwolak, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257484 · Cited by 16 · see citing works
Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma
Marjańska, A., Gałązka, P., Marjański, M., Wysocki, M. S., & Styczyński, J. (2019) · Anticancer Research · doi:10.21873/anticanres.13547 · Cited by 11 · see citing works
Li, X., Song, Z., Chen, Y., Wu, J., Jiang, D. L., Zhang, Z., Wang, Z., & Zhao, R. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03816-0 · Cited by 10 · see citing works
Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
Huo, L., Wang, C., Ding, H., Shi, X., Shan, B., Zhou, R., Liang, P., & Hou, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1190491 · Cited by 11 · see citing works
Les dysthyroïdies sous immunothérapie anti-cancéreuse
Anceau, C. C., Abeillon, J., Maillet, D., Borson‐Chazot, F., & Disse, E. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.10.005 · Cited by 9 · see citing works
Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy
Johnson, E. D., Kerrigan, K., Butler, K., & Patel, S. B. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219835912 · Cited by 8 · see citing works
Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
Brancatella, A., Lupi, I., Montanelli, L., Ricci, D., Viola, N., Sgrò, D., Antonangeli, L., Sardella, C., Brogioni, S., Piaggi, P., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab093 · Cited by 5 · see citing works
Computed tomography imaging findings of nivolumab-induced thyroid dysfunction
Oki, T., Inoue, A., Nagatani, Y., Oki, M., & Watanabe, Y. (2022) · Journal of Clinical Imaging Science · doi:10.25259/jcis_194_2021 · Cited by 4 · see citing works
Severe complications of nivolumab monotherapy in an adolescent with malignant melanoma
Grzegorczyk, A., Marczyńska, Z., Matkowski, R., Ziętek, M., Pietras, W., Latos‐Grażyńska, E., Kałwak, K., & Dachowska-Kałwak, I. (2023) · Central European Journal of Immunology · doi:10.5114/ceji.2023.130864 · Cited by 3 · see citing works
Immunotherapy and Thyroid Dysfunction
Gregorio, M. L., Gómez, J., Arora, S., Ramachandran, A., & Takalkar, A. M. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003074 · Cited by 2 · see citing works
Management of thyrotoxicosis induced by PD1 or PD-L1 blockade
Brancatella, A., Lupi, I., Viola, N., Sgrò, D., Montanelli, L., Sardella, C., Molinaro, E., Piaggi, P., Elisei, R., Marcocci, C., et al. (2020) · Endocrine Abstracts · doi:10.1530/endoabs.70.aep875 · Cited by 1 · see citing works
Burchés, F. M. J., Perez, L. A., & Merino, T. J. F. (2018) · Clinical Medical Reviews and Case Reports · doi:10.23937/2378-3656/1410235
Lechner, M. G., Patel, A. Y., Hugo, W., Angell, T. E., Chen, H.-C., Pioso, M. S., Hoang, A. T., Yakobian, N., McCarthy, E. C., Rodrı́guez, E., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-609476/v1
Management of thyrotoxicosis induced by PD1 or PD-L1 blockade
Brancatella, A., Lupi, I., Viola, N., Sgrò, D., Montanelli, L., Sardella, C., Molinaro, E., Piaggi, P., Elisei, R., Marcocci, C., et al. (2021) · Endocrine Abstracts · doi:10.1530/endoabs.73.aep875
Management of thyrotoxicosis induced by PD1 or PD-L1 blockade
Brancatella, A., Lupi, I., Viola, N., Sgrò, D., Montanelli, L., Sardella, C., Molinaro, E., Piaggi, P., Elisei, R., Marcocci, C., et al. (2021) · Endocrine Abstracts · doi:10.1530/endoabs.73aep875
Cancer immunotherapy-associated endocrine complications and treatment strategies
Sen, K., Adhikari, M., Biswas, C., Maity, S., Chatterjee, A., & Pramanick, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95114-2.00010-8
Endocrine toxicity of cancer immunotherapy
Das, N., Tarenia, S. S., & Kalra, S. (2024) · International Journal of Molecular and Immuno Oncology · doi:10.25259/ijmio_19_2024
Symptoms, symptom burden, and influencing factors in patients treated with Nivolumab
Ozdemir, F. A., Yıldırım, D., ÇELİK, M., & Can, G. (2026) · Immunotherapy · doi:10.1080/1750743x.2026.2626243
- Authors
- Yamazaki, H., Iwasaki, H., Yamashita, T., Yoshida, T., Suganuma, N., Yamanaka, T., Masudo, K., NAKAYAMA, H., Kohagura, K., Rino, Y., & Masuda, M.
- Affiliations
- Kanagawa Cancer Center (JP)
- Yokohama City University Medical Center (JP)
- Yokohama City University (JP)
- ORCID
- Venue
- In Vivo
- Published
- 2017-11-05
- Volume
- 31
- Issue
- 6
- Pages
- 1225-1228
- ISSN
- 0258-851X (ISSN-L)
- 1791-7549
- PMC
- PMC5756657
- OpenAlex
- W2768027940
- Cited by
- 28
- References
- 12
- Citations by year
- 2026: 1 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 8 · 2020: 4 · 2019: 5 · 2018: 3
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- In Vivo (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- nivolumab, thyroid dysfunction, immune checkpoint inhibitors, non-small cell lung cancer, risk factors, dose-dependent toxicity, incidence, adverse drug reactions
- MeSH terms
- Nivolumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Female, Humans, Male, Middle Aged, Risk Factors, Thyroid Diseases, Thyroid Gland
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
